High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis

Laboratory Investigation

Volumn 88, Issue 2, 2008, Pages 144-152

  Oh, Bong Kyeong ^a   Kim, Haeryoung ^b   Park, Young Nyun ^a   Yoo, Jeong Eun ^a   Choi, Jinsub ^a   Kim, Kyung Sik ^a   Lee, Jae Jung ^a   Park, Chanil ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Hepatocellular carcinoma; hTERT; Multipolar mitosis; Prognosis; Telomerase; Telomere

Indexed keywords

CYTOKERATIN 19; TELOMERASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CHROMOSOMAL INSTABILITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; FEMALE; HUMANS; KERATIN-19; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOSIS; PROGNOSIS; RNA, MESSENGER; TELOMERASE; TELOMERE;

EID: 38549159145     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700710     Document Type: Article

References (48)

1. Collins K. Mammalian telomeres and telomerase. Curr Opin Cell Biol 2000;12:378-383.
2. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science 2002;297:565-569.
3. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-68.
4. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959.
5. Ishikawa F. Telomere crisis, the driving force in cancer cell evolution. Biochem Biophys Res Commun 1997;230:1-6.
6. Murnane JP, Sabatier L. Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. Bioessays 2004;26:1164-1174.
7. Gisselsson D, Hoglund M. Connecting mitotic instability and chromosome aberrations in cancer-can telomeres bridge the gap? Semin Cancer Biol 2005;15:13-23.
8. Gisselsson D, Jonson T, Yu C. Centrosomal abnormalities, multipolar mitosis, and chromosomal instability in head and neck tumours with dysfunctional telomeres. Br J Cancer 2002;87:202-207.
9. Gisselsson D, Lv M, Tsao SW, et al. Telomere-mediated mitotic disturbance in immortalized ovarian epithelial cells reproduce chromosomal losses and breakpoints from ovarian carcinoma. Gene Chromosomes Cancer 2005;42:22-33.
10. Oh BK, Chae KJ, Park C, et al. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. J Hepatol 2003;39:786-792.
11. Oh BK, Kim YJ, Park C, et al. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol 2005;166:73-80.
12. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-1773.
13. Plentz RR, Caselitz M, Bleck JS, et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatocellular carcinoma. Hepatology 2004;40:80-86.
14. Rudolph KL, Millard M, Bosenberg MW, et al. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001;28:155-159.
15. Kruk PA, Rampino NJ, Bohr VA. DNA damage and repair in telomeres: relation to aging. Proc Natl Acad Sci USA 1995;92:258-262.
16. Oh BK, Chae KJ, Park C, et al. Molecular analysis of PinX1 in human hepatocellular carcinoma. Oncol Rep 2004;12:861-866.
17. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004;10:3317-3326.
18. Gisselsson D, Jonson T, Petersen A, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA 2001;98:12683-12688.
19. Plentz RR, Park YN, Lechel A, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 2007;45:968-976.
20. Nakajima T, Katagishi T, Moriguchi M, et al. Tumor size-independence of telomere length indicates an aggressive feature of HCC. Biochem Biophys Res Commun 2004;325:1131-1135.
21. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004;22:1807-1814.
22. Garcia-Aranda C, de Juan C, Diaz-Lopez A, et al. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma: prognostic indications. Cancer 2006;106:541-551.
23. Engelhardt M, Drullinsky P, Guillem J, et al. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res 1997;3:1931-1941.
24. Patel MM, Parekh LJ, Jha FP, et al. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck 2002;24:1060-1067.
25. Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer 2006;119:2255-2260.
26. Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006;107:1391-1399.
27. Nagao K, Tomimatsu M, Endo H, et al. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol 1999;34:83-87.
28. Hisatomi H, Nagao K, Kanamaru T, et al. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol 1999;14:727-732.
29. Takahashi S, Kitamoto M, Takaishi H, et al. Expression of telomerase component genes in hepatocellular carcinomas. Eur J Cancer 2000;36:496-502.
30. Saretzki G, Petersen S, Petersen I, et al. hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines. Cancer Lett 2002;176:81-91.
31. Suda T, Isokawa O, Aoyagi Y, et al. Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology 1998;27:402-406.
32. Kobayashi T, Kubota K, Takayama T, et al. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 2001;181:284-288.
33. Kishimoto K, Fujimoto J, Takeuchi M, et al. Telomerase activity in hepatocellular carcinoma and adjacent liver tissues. J Surg Oncol 1998;69:119-124.
34. Gertler R, Rosenberg R, Stricker D, et al. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer 2002;95:2103-2111.
35. Tabori U, Ma J, Carter M, et al. Human telomere reverse transcriptase expression predicts progression and survival and pediatric intracranial ependymoma. J Clin Oncol 2006;24:1522-1528.
36. Wilkens L, Flemming P, Gebel M, et al. Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of HCC. Proc Natl Acad Sci USA 2004;101:1309-1314.
37. Farazi PA, Glickman J, Jiang S, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003;63:5021-5027.
38. Lechel A, Holstege H, Begus Y, et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 2007;132:1465-1475.
39. Ohyashiki JH, Sashida G, Tauchi T, et al. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002;21:680-687.
40. Ju Z, Rudolph KL. Telomeres and telomerase in cancer stem cells. Eur J Cancer 2006;42:1197-1203.
41. Hiyama E, Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007;96:1020-1024.
42. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818-3822.
43. Wu PC, Lai VC, Fang JW, et al. Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of bipotential progenitor cells. J Hepatol 1999;31:965-966.
44. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40:298-304.
45. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49:138-151.
46. Lee J-S, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
47. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-857.
48. Yoon DS, Jeong J, Park YN, et al. Expression of biliary antigen and its clinical significance in hepatocellular carcinoma. Yonsei Med J 1999;40:472-477.